(1) Neuromyelitis optica spectrum disorder, also known as neuromyelitis optica (NMO), is a condition arising from complement system reactions caused by NMO-IgG; it causes inflammatory response of the central nervous system and demyelination representative of nerve damage. Developed with a novel bispecific antibody design, B2067 produces targeted blockage of NMO-antibody-binding proteins and the complement system’s signaling pathway. There are no similar products on the globe;

(2) On the one hand, B2067 produces competitive inhibition by targeting NMO-autoantibody-binding proteins to reduce attack on the cells from NMO-antibodies. On the other hand, B2067 targets the critical proteins of the complement system’s signaling pathway to block complement system reactions, thereby producing double inhibition.